

## Dissemination of Case Studies on Ganotherapy

*H. Rahman, S. Rahman, A. Rahman, & K. Rahman*

Practical Action of Intermediate Technology Development Group, House No-32, Road No-13/A, Dhanmondi, Dhaka-1209; Ganex Bangladesh (Pvt.) Ltd., Wali Center (3rd & 4th Floor), 74 Gulshan Avenue, Gulshan-1, Dhaka-1212, Bangladesh, email: [habibur@bdcom.com](mailto:habibur@bdcom.com), [habib@itdg.bdmail.net](mailto:habib@itdg.bdmail.net)

The treatment of various ailments through Ganotherapy has been initiated very recently in India and is now under experiment. However, the experiment has found some advances in the treatment of various ailments, which has been revealed through observations of different patients' ages ranging from 5 to 65 years. The time span of the ailments from which the patients suffered was 1.5 to 13 years. The purpose of the observation was to evaluate the effectiveness of the prescribed *Ganoderma* spp. capsules. The efforts were intended for promoting alternative medication for curing and maintaining health and at the same time creating social acceptance, adaptation, and affordability of this treatment among a greater segment of people.

During the study period, there were 20 different patients closely monitored after ingesting 500 mg capsules in various doses. All the cases were

documented in a systematic way. The patients were suffering from low blood pressure (1), asthma (4), liver and stomach problem (1), obesity and health maintaining (1), prostate cancer (1), diabetes (1), paralysis (1), uterus tumor (1), gangrene (1), blood dysentery (1), respiratory and weakness problem (1), gastritis and gout (1), sinusitis and teeth problem (1), piles (1), rheumatic fever and brain disorder (1), kidney problem (1), and gynecological unwanted pains (1). According to our observations, it has been found that 80% of the patients were cured and are now leading a better quality of daily life.

It may be urged and stressed that a wider scope of clinical research work on Ganotherapy in the country is needed. International collaborative research and development activity is encouraged and welcomed on an urgent basis to continue clinical research.